Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics for eye care and infectious disease prevention. The company's website is www.tarsuspharm.com.

Tarsus launched XDEMVY (lotilaner ophthalmic solution) 0.25% in August 2023 following FDA approval in July 2023. XDEMVY is the first and only FDA-approved therapeutic for Demodex blepharitis, a disease caused by infestation of Demodex mites that affects an estimated 25 million Americans. The drug works by paralyzing and eradicating mites through selective inhibition of parasite-specific GABA-chloride channels. XDEMVY has generated over $646 million in net product sales since launch.

The company's pipeline includes several investigational product candidates utilizing the lotilaner active pharmaceutical ingredient. TP-04 is a sterile aqueous gel formulation in development for ocular rosacea, a chronic eye disease affecting approximately 15 to 18 million Americans with no current FDA-approved treatments. TP-05 is an oral tablet formulation being developed for Lyme disease prophylaxis, targeting the approximately 80 million Americans at risk of Lyme disease exposure, with roughly 400,000 estimated cases annually in the United States.

Tarsus has completed seven clinical trials for XDEMVY in Demodex blepharitis, including Phase 3 and Phase 2b/3 pivotal trials, all of which met primary and secondary endpoints with favorable safety profiles. The company has also completed clinical trials evaluating XDEMVY in Demodex blepharitis patients with Meibomian Gland Disease, another common eye condition affecting 30 to 40 million Americans.

The company licenses its core intellectual property from Elanco Tiergesundheit AG and has entered into a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for TP-03 rights in China. Tarsus retains global rights to all other indications for its product candidates. The company employs a specialty sales force focused on eye care professionals and has implemented direct-to-consumer marketing campaigns to build disease awareness and drive patient engagement with XDEMVY.